Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting

April 22, 2026 updated by: Hyo-Soo Kim, Seoul National University Hospital

EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry

The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES in the real world.

The investigators will compare EES (Xience/Promus, prospective arm) with sirolimus-eluting stent (SES, Cypher, retrospective arm).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

3056

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • South Korea
      • Cheonan, South Korea
        • Soon Chun Hyang University Hospital Cheonan
      • Cheonan, South Korea
        • Dankook University Hospital
      • Cheongju-si, South Korea
        • Chungbuk National University Hospital
      • Gwangju, South Korea
        • Kwangju Veterans Hospital
      • Iksan, South Korea
        • Wonkwang University Hospital
      • Iksan, South Korea
        • Chonbuk National University Hospital
      • Ilsan, South Korea
        • Inje University Ilsan Paik Hospital
      • Inchon, South Korea
        • Gachon Kil Medical Center
      • Jeonju, South Korea
        • Presbyterian Medical Center
      • Jinju, South Korea
        • Gyeongsang National University Hospital
      • Pusan, South Korea
        • Inje University Pusan Paik Hospital
      • Seongnam, South Korea
        • Seoul National University Bundang Hospital
      • Seoul, South Korea
        • Samsung Medical Center
      • Seoul, South Korea
        • Seoul National University Hospital
      • Seoul, South Korea
        • Gangnam Severance Hospital
      • Seoul, South Korea
        • Kyung Hee University Medical Center
      • Seoul, South Korea
        • Yonsei University Medical Center
      • Suncheon, South Korea
        • St. Carollo Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Approximately 4000 patients derived from a population of patients receiving percutaneous coronary intervention for ischemic heart disease will be enrolled in the present registry.

Description

Inclusion Criteria:

  • The patient agrees to participate in this study by signing the informed consent form.
  • Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.

Exclusion Criteria:

  • There are no exclusion criteria for this registry.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Xience/Promus
Active prospective registration of patients receiving everolimus eluting stent
Device: Xience/Promus
Active prospective registration of patients receiving everolimus-eluting stent
Other Names:
  • EES
Cypher
Retrospective historical controls that received sirolimus-eluting stent
Device: Cypher
Retrospective historical controls that received sirolimus-eluting stent
Other Names:
  • SES

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Major Adverse Cardiac Events (composite of cardiac death, non-fatal MI, target lesion revascularization)
Time Frame: 12 months
12 months

Secondary Outcome Measures

Outcome Measure
Time Frame
In-stent & In-segment Late Loss
Time Frame: 9 months
9 months
Stent Thrombosis
Time Frame: 1 year
1 year
Target Vessel Failure (composite of cardiac death, MI, and TVR)
Time Frame: 12 months
12 months
Any death, cardiac death, MI, TLR, TVR
Time Frame: 1 year
1 year
Composite rate of cardiac death and any MI
Time Frame: 1 year
1 year
Composite rate of all death and any MI
Time Frame: 1 year
1 year
Composite rate of all death, any MI (Q-wave and non Q-wave) and any repeat revascularization
Time Frame: 1 year
1 year
Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
Time Frame: 1 year
1 year
Clinical device and procedural success
Time Frame: During the health care facility stay
During the health care facility stay

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Collaborators

Boston Scientific Corporation
Abbott

Investigators

  • Study Chair: Hyo-Soo Kim, MD,PhD, Seoul National University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2008

Primary Completion (Actual)

January 1, 2014

Study Completion (Actual)

January 1, 2014

Study Registration Dates

First Submitted

August 14, 2009

First Submitted That Met QC Criteria

August 17, 2009

First Posted (Estimated)

August 18, 2009

Study Record Updates

Last Update Posted (Actual)

April 27, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EXCELLENT-REGISTRY

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe